Octreotide acetate in dominant cystoid macular dystrophy.

Abstract

Item does not contain fulltextPURPOSE: Dominant cystoid macular degeneration (DCMD) is an autosomal dominant trait of cystoid macular edema with poor visual prognosis. Until now, no efficient treatments for DCMD have been reported. The authors evaluated a somatostatin-analogue (octreotide acetate) as treatment for DCMD. METHODS: The authors treated four patients with early DCMD by intramuscular longacting octreotide acetate, 20 mg every 4 weeks for 1 year. In addition to general ophthalmologic examination the authors performed fluorescein angiography (FA) before and after treatment. RESULTS: Seven out of eight eyes showed improvement on FA and stabilization of visual acuity. CONCLUSIONS: Somatostatin-analogues may reduce cystoid edema in DCMD and may thus prevent disease-related visual loss